¥xÆW¤HÂå¬É¡R¤@¯ëÂå¾Çªº°Q½×

1.ºC©ÊÅè²Ó­M©Ê¥Õ¦å¯f¥HLegg-Calve-Perthes¯g¥X²{--½Í¥þ¨­ÅéÀ˪º­«­n 2.¦b¬üªA°È¨àµ£Âå°|¤§¸gÅç½Í 3.¦³®Ú¾ÚªºÂåÀø¤Î«ü¾É¤è°w:(¤@)²L½ÍEvidence-Based Clinical Practice and Guideline 4.¦³®Ú¾ÚªºÂåÀø¤Î«ü¾É¤è°w:(¤G)­ìµo©Ê¯Ê¦å¤pªOµµ´³¶Eªv«ü¾É¤è°w¤§¨Ò Link to: JINGFU EXTRA ´ººÖ¥~°T Link to:TAIWANESE MEDICAL COMMUNITY ¥x ÆW Âå ¾Ç ±M ¥Z Link to: HAKKA TAIWANESE SPECCIAL PUBLICATION «È ¥x »y ±M ¥Z ¦U ´Á Link to:TAIWANESE HAKKA ¥x ÆW «È ®a (ENGLISH) Link to:HAKKA TAIWANESE RESOURCES «È ¥x »y ¸ê ®Æ ®w Link to:HAKKA TAIWANESE HAKKA CULURE ¥x ÆW «È ®a ¤å ¤Æ ±M ¥Z Link to: TAIWAN SPECIAL PUBLICATION ¥x ÆW ±M ¥Z

ºC©ÊÅè²Ó­M©Ê¥Õ¦å¯f¥HLegg-Calve-Perthes¯g¥X²{ --½Í¥þ¨­ÅéÀ˪º­«­n

¦¶¯u¤@*

¡]¤@¡^«e¨¥ ¬ì¾Çª¾ÃÑ·U¨Ó·U¶i®i¡AÀ³¥Î³o·s¬ì¾Çªºª¾ÃÑ´N²£¥Í§ó¦h¥i¥Î¨ÓÀ°¦£¶EÂ_ ªº·s»ö¾¹¤Î·s¹êÅç«Çªº¤èªk¡C²@µLºÃ°Ýªº¡A³o¨Ç»ö¾¹¤Î¹êÅç«Ç¶EÂ_ªk¥i¥Î¨ÓÀ°¦£ §ó·Ç½T¦a¶EÂ_¦UÂø¯fºÃ¯g¡C¤Ï¹L¨Ó¨­ÅéÀˬd¥H¤Î¤@¯ë²³æ«K©yªº¹êÅç«Ç¶EÂ_ªk¤] ±`±`¦Ó¥B·U¨Ó·U³QÂå®v©Ò©¿²¤©Î§Ñ°O¡C±M¬ìÂå®v¤×¨ä·|©¿²¤¥þ¨­¨­ÅéÀˬd¡A¥u°µ ¦Û¤v±M¬ì»â°ì¤ºªºÀˬd©ÎÀËÅç¡C¥Ñ©ó³o¨Ç©ù¶Qªº·s¬ì§Þ»ö¾¹·U¨Ó·U´¶¹M¡A³oºØÀË Åç¤]·U¨Ó·U³QÀݥΡA´£°ª¤FÂåÀø¶O¥Î¡C¤×¦³¬ÆªÌ¡A¦]¬°©¿²¤¥þ¨­ÅéÀˤβ³æ¹êÅç «Ç¶EÂ_¡A¤]±`·|©ì©µ¤F¥¿½Tªº¶EÂ_¦Ó©µ»~¤FªvÀø¡C Legg-Calve-Perthes¯g¬OªÑ°©ÀY¡]femoral head¡^µL¦åºÞ©ÊÃa¦º ¡]avascular necrosis¡^¤Þ°_ªº¡A³Ì±`µo¥Í©ó¤p«Ä310·³¡CÁöµM¯u¥¿ªº¯f¦]¨Ã¤£¤Q ¤À²M·¡¡A¦ý¦³«Ü¦h¯e¯f»P³oºØµL¦åºÞ©ÊÃa¦º¦³Ãö³s¡C³Ìªñ§Ú­Ì³sÄòµo²{¤G¦ì¯f¤H ¬O¥ÑºC©ÊÅè²Ó­M©Ê¥Õ¦å²y¡]chronic myelocytic leukemia¡^ ¤ÞµoLegg-Calve -Perthes¯g¡C¦ý¦b Ų§O¶EÂ_®É©¿²¤¤F³o¥i¯à©Ê¦Ó¥¼¥[¥H¦Ò¼{¨ìºC©Ê¥Õ¦å²y¡C ¨ä ¤¤¤@¨Ò§ó¦]¦Ó©µ»~¤F¶EÂ_¡C Ų§O¶EÂ_¤]­n¤ß«ä¼e¼s¡A¦h¥[¦Ò¼{¦UºØ¥i¯à¡A¤~¸û¤£·|¦³¥¢»~¡C¤U­±¥ý ³ø¾É§Ú­Ìªº¤@­Ó¯f¨Ò¡A¥H«á¦A°Q½×¡A³o¯f¤H¦p¦ó¦]¥¼°µ¥þ¨­ÅéÀˤΥ¼¦Ò¼{¨ì¥Ñ ¦å²G¯e¯f¥i¯à¤Þ°_¸}µh¤Î¶_¦æ¡A¥¼°µÂ²³æªºÀËÅç¡A¯f¤H¦]¦Ó©µ»~¤F¶EÂ_¡C¬Æ¦Ü³Ì «áµo²{µÊ¸~¤j»~¥H¬°¬O¸¡½F¡A¥Î©ù¶Qªº¹q¸£±½ºË¤´¥¼¯à¶EÂ_¡A©¿²¤¤F³Ì°ò¥»ªº¦å ²GÀˬd¡C³o¬O¤@­Ó«Ü¦³»ù­ÈªºÂå¾Ç±Ð¨|¯f¨Ò¡A§Ú­ÌÀ³¥i¾Ç²ß¨Ã§ï¶i¡C ¡]¤G¡^¯f¨Ò³ø§i ¤@¦ì¤Q·³¦hªº¤k«Ä¦b¦í°|¤»­Ó¦h¤ë«e´N²¤¦³¥ªÃä¤j»Lµh¡A¨«¸ô®É¤]¦³¨Ç ¶_¡C¤p¨à¬ìÂå®v¬Ý¤£¥X©Ò¥HµM¦ÓÂà°eµ¹°©¬ìÂå®v¶Eªv¡C¦í°|¤»­Ó¤ë«e¤]°µ¹LX¥ú Àˬd¡A¨º®ÉX¥úÀˬd»{¬°¥¿±`¡C¤j»LµhÁö¤£¬Æ¼F®`¦ý«oº¥¥[ÄY­«¡A¦í°|«e¨â­Ó¤ë ¤SÂà°eµ¹¥t¤@°©¬ìÂå®v¶Eªv¡C³o¦¸X¥úÀˬd´N¦b¥ªÃäªÑ°© ÀY¦³¨å«¬ªºLegg-Calve -Perthesªº¯fÅÜ¡C©Ò¥H«ü¥Ü¯f¤H¨Ï¥ÎÏ^§ú¡A´î¤Ö¨Ï¥Î¥ª»L©Ó¾á­«¶qªº¾÷·|¡A¦ý¬O »Lµh¨Ã¥¼´î»´¡A¯f¤H¤]§ó»a¥Õ¨Ç¤Î¾ã¨­¤£µÎªA¤Î­¹¼¤º¥§C¡C¦í°|¨º¤Ñ¦A¥h¬Ý¤p¨à ¬ìÂå®v¡Aµo²{¯f¤H¸¡³¡¦³«Ü¤jªº½F¡A½F´X¥G¦û¾Ú¾ã­Ó¸¡³¡¡C ¯f¤H°¨¤WÂà°eµ¹«æ¶E³B¤Î¤p¨à¥~¬ì¡A¦]·í¤Ñ¬O¬P´Á¤»¡A°e¥h«æ¶E³B¥s¤p ¨à¥~¬ì·|¶E¡C¤p¨à¥~¬ì²Ä¤@­ÓÂåÅñ¬O§@¸¡³¡¹q¸£±½ºË¡Aµo²{¬OµÊ·¥«×¸~¤j¡]24¡Ñ 12¡Ñ15¤½¤À¡^¡CµM«á¥s¤p¨à¦å²GÀù¸~½F¬ì·|¶E¡C¥u°µ´¶³q¦å²G²Ó­M¼Æ¡]Complete Blood Count¡ACBC¡^µo²{¥Õ¦å²y450,000/£gl ¦Ó¥Õ¦å²y¤À§O¬O 2%myeloblasts¡A 18% myelocytes¡A 14% metamyelocytes¡A 4% band¤Î15% segmented neutrophils¡A2%lymphocytes¡A4%monocytes¤Î5%basophils¡C¦å¬õ¯À¬O11.3g/dl ¦Ó¦å¤pªO¬O179,000/£gl¡A¤@¯ë¦å²G¤Æ¾Ç¥]¬A¨xµÇ¾÷¯à¡B§¿»Ä¤Î¦å¾®©TÀËÅç³£¥¿±`¡A ¥u¦³LDH¡]Lactic Dehydro genase ¡^ ¼W°ª¡C °©Åè¬ï¨ëµo²{¨ä²Ó­M¼Æ¼W¥[¡A°©Åè©Ê²Ó­M¤×¨ä¬O¥¼¦¨¼ô«¬²Ó­M¼W¥[«Ü¦h¡A °©Åè¼Ë²Ó­M¨t¦C¤Î¬õ¦å²y¨t¦C¤§¤ñ¡]M¡GEratio¡^¬O10¡G1¡C°©Åè©â¨ú²G°µ²Ó­M ¿ò¶Ç¾ÇÀˬd¬O100%¦³Philadelphia¬V¦âÅé¡qt¡]9,22¡^(q34;q11.2)¡r¦Ó¥B20%¤§²Ó ­M¨ä¬V¦âÅé¦bq21-31³B¦³Intertitial deletion¡C ¦í°|«á¡A¯f¤H±µ¨üHydroxyurea, Cytosine arabinoside¤Î £\-interferon-2bªºªvÀø¡C¯f¤Hªº¥Õ¦å²y¤@¬P´Á¤º«Ü§Ö´N´î§C¨ì5,000/£gl¥H¤U¡C ¥H«á¤Æ¾ÇªvÀøªkÄ~Äò«O«ù¥Õ¦å²y¦b5,000/£gl¥ª¥k¡CµÊŦ¤]º¥º¥´î¤p¡A«á¨Ó¥u¯àºN ¨ìµÊªº¦y³¡¦Ó¤w¡C¦ý¬O6­Ó¤ë«á°©Åè¬ï¨ëÀËÅ礴¦³Philadelphia¬V¦âÅ骺²Ó­M¡AÁö µMÅã·LÃè¤U¡A°©Åè²Ó­M¬Ý°_¨Ó¬O¥¿±`¡C ¤»­Ó¤ë¤Æ¾ÇªvÀø«á¡A¦A°µX¥úÀˬd¡AªÑ°©ÀY¦³ÅãµÛªº¶i¨B¡A¤Æ¾ÇªvÀø¤C­Ó ¤ë«á¡A±q¤@µL¦å½tÃö«Y¡A¦ý¤HÃþ²O¤Ú²y§Ü­ì¬Û¦Pªº®½Ãت̪º°©Åè°µ¤F°©Åè²¾´Ó³N ¡C²¾´Ó«á¤w¤T¦~¥b¡A¦oªº°©Åè¤Î¥½±é¦å²G¥¿±`µL¥Õ¦å¯f¸ñ¶H¡C²¾´Ó¤@¦~«áªº°©Åè ¬ï¨ëªº²Ó­M¿ò¶Ç¾ÇÀËÅç¤wµLPhiladelphia¬V¦âÅé¡C ¡]¤T¡^°Q½×¡G ±q³o¯f¨Ò¥i¥H¾Ç²ß´XÂI¹ê»Ú°ÝÃD¡A³o¬O¤@­Ó«Ü¦³±Ð¨|»ù­Èªº¯f¨Ò¡C³o¯f ¨Ò§i¶D§Ú­Ì¶EÂ_¯f ¤H¥²¶·­n¦³¼eÁ諸«äºû°µÅ²§O¶EÂ_¡]Differential Diagnosis ¡^¡CÁöµMºC©ÊÅè²Ó­M©Ê¥Õ¦å²y¯f¥HLegg-Calve-Perthes¯g§e²{¦bÂå¾Ç¤åÄm¤¤´¿¦³ ¤H³ø§i¹L¡]1¡A2¡^¡A¦ý¤@¯ë¤p¨à¬ìªº±Ð¬ì®Ñ¡]3-6¡^ ¤Î°©¬ì±Ð¬ì®Ñ¡]7¡A8¡^³£¨S ¦³¦C¥X¡C ³Ì±`¨£ªº®Ñ¥»´£¥X³o¯f¯g¸òÅIª¬³h¦å(sickle cell anemia¡^¡Aªø´Á¨Ï¥ÎµÇ ¤W¸¢¯À¡A²Óµß©Îµ²®ÖµßÃö¸`ª¢¡B«C¦~­·ÀãÃö¸`ª¢µ¥µ¥¦³Ãö¡C¨â¥»°©¬ì±Ð¬ì®Ñ¦C¦³ ¤Q¤CºØ¤£¦Pªº¯e¯f»ÝŲ§O¶EÂ_¡A¦ý¨S´£¤ÎºC©ÊÅè©Ê¥Õ¦å¯fªº¥i¯à©Ê¡C³o¨â®Ñªº§@ ªÌ¦b°Q½×¤¤½T±ÀÂ˰µ¦å²G²Ó­M¼Æ¡]CBC¡^¨Ó±Æ°£·P¬Vµoª¢ªº°Ñ¦Ò¡A¦ý¤å¤¤«o¨S¦³ ´£¤Î¤]¥i¥H¥Î¨ÓÀ°¦£¶EÂ_¥Õ¦å¯f¡C¥Õ¦å¯f¤£½×«æ©Ê¤ÎºC©Ê³£¦³¥i¯à¦³»Lµh¤Î¶_¦æ ªº¥i¯à¡AÁöµM¤Þ°_ªº¾÷Âà¥i¯à¤£¤Ó¤@¼Ë¡C ³o¯f¨Ò§ó»¡©ú¥þ¨­¨­ÅéÀˬdªº­«­n¡C³o¯f¤H¦³ºC©ÊÅè©Ê¥Õ¦å¯f¬Û·í¤[¡A µÊ¸~¤j¦­´N¸Ó¦³¡C­Y¦³°µ¸Ô²Óªº¥þ¨­¨­ÅéÀˬd¡AµÊ¸~¤jÀ³¦­¥iµo²{¡A«h¥Õ¦å¯f¥i ´£¦­¶EÂ_¥X¨Ó¡C³o¯f¨Ò¤]»¡©ú²³æªº¹êÅç«ÇÀˬd¡A¦p¦å²Ó­M¼Æ¡]CBC¡^¤ñ©ù¶Qªº ¹q¸£±½ºË¨Ó±o¦³¥Î¡C­Y¦å²Ó­M¼Æ¤ñ¹q¸£±½ºË¥ý°µ¡A¥Õ¦å¯f¦­´N¥i¶EÂ_¥X¨Ó¡A¹q¸£ ±½ºË®Ú¥»´N¤£»Ý­n¡C³o¤]¦A¦¸»¡©ú¨­ÅéÀˬdªº­«­n¡A³o¯f¤HµÊ¸~¤jÁö¤j¨ì´X¥G¦û ¾Ú¾ã­Ó¸¡µÄ¡A¥J²ÓÀˬdÀ³¥iÃhºÃ¬O¦³µÊ¸~¤jªº¥i¯à¡A­YÃhºÃµÊ¸~¤j¡A¦å²Ó­M¼ÆÀ³ ¬O­º¥ý¥h°µªºÀËÅç¡A¦Ó«D¹q¸£±½ºË¡C Ų§O¶EÂ_ªº­«­n©Ê¤]À³¬O±q³o¯f¨Ò¤¤¾Ç²ß¨ì¡A°l®Ú¨ì©³­YÀˬd¯f¤H®É¡A¦³ ·Q¨ì¦UºØ¤£¦P ±¡ ªp·|¤Þ°_¤j»Lµh¤Î¶_¦æ®É¡A´N·|¥h¦n¦nÀˬd¯f¤H¡C­YX¥ú¶EÂ_¥X Legg-Calve-Perthes Disease®É¡A­Y·Q¨ìºC©ÊÅè©Ê²Ó­M¤]¥i¯à¤Þ°_¦p¦¹¯fÅܮɡA¨º À³´N¸Ó¸Ô¬dµÊ¸~¤j§_¡H¦å²G¥Õ¦å²y¦p¦ó¡HÁ`¦Ó¨¥¤§¡A³o¯f¨Ò»¡©ú¡A­Y¤p«Ä¦³Legg- Calve-Perthes¯f®É¡AÀ³¦h°µÅ²§O¶EÂ_¡A¦Ò¼{¨ä¥¦¦UºØ ¯f ªº¥i¯à¡AºC©ÊÅè©Ê²Ó­M ¥Õ¦å²y¬O¨ä¤¤¤@ºØ¡C¥Ñ³o¯f¨Òªº©µ½w¶EÂ_¡A§ó»¡©ú¥þ¨­ÅéÀ˪º­«­n¡C (¥|¡^¤åÄm 1) Salimi Z, Vas W, Sundaram M. Avascular bone necrosis in an untreated case of chronic myelogenous leukemia. Skeletal Radiology 1988;17:353-355 2) Hanif I, Mahmoud H, Pui C-H. Avascular femoral head necrosis in pediatric cancer patients. Med and Pediat Oncol 1993;21:655-660 3) Behrman RE, Kliegman RM , Arvin AM eds. Nelson Textbook of Pediatrics.15th ed., Philadelphia: WB Saunders Co. 1996:1949-51 4) Avery ME, First LR eds. Pediatric Medicine. 2nd ed. Baltimore: Williams & Wilkins. 1994:1425-6 5) Rudolph AM, Hoffman JIE, Rudolph CD eds. Rudolph’ s Pediatrics. 19th ed. Norwalk, Connecticut: Appleton & Lange. 1991:1943-4 6) Oski FA, DeAngelis CD, Feigin RD, Warshaw JB eds. Principles and Practice of Pediatrics. Philadelphia: Lippincott. 1990: 942-943 7) Weinstein SL, Buckwalter JA eds. Turek’ s Orthopedics, Principles and Their Application. 5th ed. Philadelphia: Lippincott.1994: 495-509. 8) Morrissy, RT ed. Pediatric Orthopedics. 4th ed. Philadelphia: Lippincott. 1996: 951-991. ¡]ÂÔÁ±ç·ç¬Ã¤p©j¥´¦r¡^ ----------------------------------------------------------------------------------------------------------------------------- *±KĬ¨½¦{¸t¸ô©ö¥«¸t¸ô©ö¤j¾Ç¤ÎCardinal Glennon¨àµ£Âå°|¤p¨à¦å²GÀù½F¬ì

¦b¬üªA°È¨àµ£Âå°|¤§¸gÅç½Í ¦¶¯u¤@

¡@¡@·í¬ü°ê¤p¨à¬ìÂå®v³o»ò¦h¦~¡A¸g¾ú¹L5­ÓÂå°|ªº¤£¦P¸gÅç¡C¦b½ü¬y¹ê²ßÂå®v®ÉªA°ÈªºªÀ °ÏÂå°|(Community Hospital)¡A¤p¨à¬ì¦í°|Âå®vªº2­Óºî¦XÂå°|¡A¤p¨à¦¸±M¬ì°V½m¤§¨àµ£Âå °|¥H¤Î¥Ø«e¥þ¾ªA°Èªº¨àµ£Âå°|¡C¨C­ÓÂå°|¹ï¤p¨à¯f±wºA«×¤ÎÂå°|¤§¸gÀçµ¥µ¥«D±`¤£¦P¡A¶È ±N¦Û¤v¸gÅç¼g¥X¡A§Æ±æ¦³§U©ó¥xÆW¨àµ£Âå°|¤§Äw«Ø¡C ¡@¡@²Ä¤@¦~¨ìªi¤h¹yªº¤@ªÀ°ÏÂå°|¡A¦b¤p¨à¬ì¨â­Ó¤ëªº¦L¶H«D±`¼Ò½k¡A¦^·Q°_¨Ó¥D­n¬O¨ºÂå °|¹ï¤p«Ä¤@ÂI¤]¤£ª`­«¡A¤p«Ä¤lªº¯f©Ð¨S¦³¯S§Oªº³]­p¡A»P¦¨¤H¤@¼Ë¡C°O±o¤p«Ä¤l¶}¤M®É»P ¦¨¤H¦í¦b¦P¼Ëªº¯f©Ð¡A¸ò¦¨¤H¤@¼Ëªº·ÓÅU¡C¶}·~Âå®v¤¤¤]¦³¤£¤Ö¤£¬O¤p¨à¬ìÂå®v¡A¦³¨Ç¬O¤@ ¯ë¶}·~ªº(¨º®ÉµL®a®xÂå¾Ç¬ì)¡C¤p«Ä¦b³o¦¨¤H¬°¥Dªº¤¤«¬Âå°|(¬ù400§É)¥i»¡§¹¥þ³Q©¿²¤¡C¤´ °O±o¦³­Ó¤p«Ä¨zµh°e¨Ó¦í°|¡AÁñ§Àª¢ÁÙ¬O§Ú¶EÂ_¥X¨Ó³qª¾¸Ó¶}·~Âå®v¡C³o®aªÀ°ÏÂå°|¬Û·í¤£ ¿ù¡A¤º¥~¬ìÂå®v³£¤£¿ù¡A¤]¬Oªi¤h¹y¨â®aÂå¾Ç°|ªºÁpôÂå°|¡A¦ý¤p¨à¬ì´N¬O¤£³Q­«µø¡C ¡@¡@¤p¨à¬ì¦í°|Âå®v¦b¯Ã¬ù¦{¥ß¤j¾Ç¤U«°Âå¾Ç¤¤¤ß°V½mªº¡A³o¨â¦~¦b¨â®aºî¦XÂå°|ªA°È¡A¤j ³¡¤À®É¶¡¬O¦b¦³1,000¦h§Éªº°p¥ßÂå°|¡A¤@¦~¤¤´X­Ó¤ë¦b¤j¾ÇÂå°|¡C³o¨â­Óºî¦XÂå°|¹ï¤p«Ä¸û ª`­«¡A¤p¨à¬ì¦b¦P¤@´É¼Ó¤¤¦³¦n´X¼h¡A¦³±Mªù¤p¨àªº©ñ®g½uÂå®v¤Î¤@¯ë¥~¬ìÂå®v¡C¤p¨à¬ì¤º ªº¨C­Ó¦¸±M¬ì(Subspeciality)Áö¤]¦³¡A¦ý¦UºØ¥~¬ì«hµL¤p¨à¤è­±±M®a°Ñ»P¡AÁÙ¬O¤£¤Q¤À²z·Q¡C ¨º®ÉÁö¥t³]¦³·L¶qÀËÅç«Ç¡A¦ý»Ý¯S§O½Ð¨D¡A¤j³¡¤À¤´¦bÂå°|Á`ÀËÅ糡ªù¤º¡C©ñ®g½u¬ìÁö¦³±M ªùªº¤p¨à¬ì©ñ®g½uÂå®v¡A¦ý¨S¦³¥t¥~¯S¬°¤p¨à±M¥Îªº³]³Æ¡C ¤p¨à¬ìÁö¤£¤p¦ý¦b¾ã­ÓÂå°|¤¤¤ñ¨Ò¤W¤´¤£¬Æ­«­n¡C³Ìªñ³o®aºî¦XÂå°|§â¦³Ãö¤p¨àªº¯f¤H ¶°¤¤¡A¦¨¥ß¤@¨àµ£Âå¾Ç¤¤¤ß¡AÀ³¸Ó¬O¬°¤FÀ±¸É±q«eªº¯Ê»Ø¡A¦ý¬O³o¤@¨àµ£Âå¾Ç¤¤¤ß¤´¤£¬O¿W ¥ßªº¾÷ºc¡A¥u¬O¤@­Ó¤jÂå¾Ç¤¤¤ß¤§¤@¦¨­û¡A°]°È»P¤H¨Æ¨S¦³¿W¥ß¡C ¡@¡@¦A«á¨â¦~ªº¤p¨à¦å²GÀù½F¦¸±M¬ì°V½m¬O¦b¸t¸ô©öªºµØ²±¹y¤j¾Ç¤p¨à¬ì¡C³o¤@¬ì¾ã­Ó¦b¨à µ£Âå°|¤º¡A¥D¥ô¤]­ÝÂå°|Âå°È¥D¥ô(medical director)¡C³oÂå°|¬O§¹¥þ¿W¥ßªºÂå°|¡AÂå°|¦³ ¦Û¤vªº¸³¨Æ·|¡B¦æ¬F¥DºÞ¤Î¤H¨Æ¦w±Æ¡CÂå°|»PÂå¾Ç°|¦³¦X§@ñ¬ù¡A¾ã­Ó¤p¨à¬ì¤Î¤@¨Ç±Mªù¤p ¨àªº¥~¬ì¡B¯«¸g¬ì¡B²´¬ìµ¥µ¥¤]¦bÂå°|¤º¡CÂå°|¦³¦Û¤vªºÀËÅç«Ç¡C¥i¬O·í®É¤´¦³³\¦h­«­n³¡ ªù¯Ê¡A¦p¥²»Ý¨ìºòÁ{ªº¦¨¤Hºî¦XÂå°|BarnesÂå°|¥h¡CÄ´¦p¦¹¨àµ£Âå°|¨S¦³¤â³N©Ð¡A¨S¦³©ñ®g ½u¬ì¡A¨S¦³¸Ñ­å¯f²z³]³Æ¡A³o¨Ç³]³Æ­n¥Î¦¨¤HÂå°|ªº¡C©¯¦Ó©ñ®g½u¬ì¦³¤@¼Ó±M¬°¤p¨à¬ì¨Ï¥Î¡A ¦³±Mªù¤p¨à©ñ®g½uÂå®v¦P®É¸Ñ­å¯f²z¤è­±¤]¦³¤p¨à¯f²z¤§±M®a¡AÁö¤£¤è«K¡A¦ýÁ`¦³¦U¬ì±M®a ªA°È¨àµ£¡C³oÂå°|ªº¦Õ»ó³ï¬ì¤ñ¸û¯S§O¡AÂå®v¤£ªÖ¥h¨àµ£Âå°|¡A©Ò¦³¤p¨à¦Õ»ó³ï¬ì°ÝÃD»Ý¨ì ¦¨¤HÂå°|¥h¡C ¡@¡@¦¹µØ²±¹y¤j¾Çªº¨àµ£Âå°|(¸t¸ô©ö)¡A¦b§ÚÂ÷¶}´X¦~«á¡A´X¦~«e¤S­«·s»\¤F¤@·sªºÂå°|¡A ¯f§É¼W¥[¤£¤Ö¥~¡A¤]¼W¥[¤F¶}¤M©Ð¡A¤p¨à©ñ®g½u¬ì¤]·h¤J·sªº¨àµ£Âå°|¤º¡A¦Õ»ó³ï¬ì¥ç¶}©l ²¾©¹¨àµ£Âå°|§@·~¡C³oºØ§ïÅܤ@©w¤]¬O¬°¤FÀ±¸É±q«e¨S¦³¶}¤M©Ð¤Î©ñ®g½uµ¥µ¥³]³Æªº¿ò¾Ñ¡C ¡@¡@1975¦~¤p¨à¦å²GÀù½F¬ì°V½m§¹«á¶}©l¥h§ä¾¦ì¡A§Ú¥Ó½Ð¥«¤¤¥t¤@Âå°|¸t¸ô©ö¤j¾Ç¤p¨à¬ì¡A °ÑÆ[¸Ó®Õ¦³Ãöªº¨àµ£Âå°|®É¡A¤@¬Ý¦³¶}¤M©Ð¡B¦³©ñ®g½u¬ì¡B¦³¯f²z¬ì¡A¤ñµØ²±¹y¤j¾Çªº¨àµ£ ®Ê°|§ó»ô³Æ¡A«D±`°ª¿³¨Ó´N¾¡C³o®a¬O¤Ñ¥D±Ð¤j¾Ç¡A¡uGlennon¤j¥D±Ð¨àµ£Âå°|¡v·í®É¬O¥HªA °È¯f±w¬°¥D¡AÁö¬ã¨s®ðª^¤j¤£¦pµØ²±¹y¤j¾Ç¡A«o¬O«D±`Àu¨}ªºÂåÀø¾÷ºc¡C³Ìªñ¤]ÂX®i«Ü¦h¡A §Ú¦b¦¹¤@«Ý´N¤Q¤­¦~¡A¨ä¤¤Åܤƫܦh¡A¤£¯à¸Ô­z¡A¥þ¾±Ð­û±q¥H«e¬ù10¼Æ¦W¨ì¥Ø«e40´X¤H¡C §Ú¦Û¤v¤@¦V¼ö¤ß°Ñ»PÂå°|¨Æ°È¡A±`±`§ÓÄ@·í¤@¨Ç©e­û·|©Î¨S¤H­n°µªº¤u§@¡A¦p¤@¨Ç¦P¹±ºÊ·þ (Peer review)ªº©e­û·|©ÎÄ~ÄòÂå¾Ç±Ð¨|¡A¹ï¦¹Âå°|¸û¬°¼ô±x¡A©Ò¥H¤£¹½¨ä·Ð¦a³ø¾É¡C ¡@¡@Glennon¤j¥D±Ð¨àµ£Âå°|¬O¿W¥ßªºÂå°|¡AÂå°|¦³¦Û¤vªº¸³¨Æ·|¤Î¦æ¬F¨t²Î¡AÂå°|ªº°]¬F¤Î ¤H¨Æ§¹¥þ¿W¥ß©ó¸t¸ô©ö¤j¾Ç¤§¥~¡CÂå°|¦b¸t¸ô©ö¤j¾ÇÂå°|¤ÎÂå¾Ç°|¹j¾À¡A¦³¦a¹D¬Û³s¡C¤p¨à¬ì ¤Î¨ä¥L¦U¬ì¦p¥~¬ì¡B¯f²z¬ì¡B²´¬ì¡B©ñ®g½u¬ì¡B¯«¸g¬ì¡B¦Õ»ó³ï¬ì¡Bºë¯«¬ìµ¥µ¥ªº¤p¨à³¡ªù¥þ ³¡®y¸¨©óÂå°|¤º¡CÂå°|¦³¶}¤M©Ð¡B¸Ñ­å¯f²z¤ÎÀËÅç«Ç¡A©ñ®g½u¬ì³]³Æ¥]¬A¦³¦Û¤vªºCT scanner ¤ÎMRI¡C190§Éªº¯f°|¤£¥i¯à¤°»ò³£¦³¡A¹³¤ßŦ¾ÉºÞ³N¡B©ñ®g½uªvÀø(radiation oncology)¤Î¦U ºØ¦åºÞ¾ÉºÞÄá¼vµ¥µ¥¤´­n­É§U¹j¾Fªº¤j¾ÇÂå°|¡C¦ý¬O¤j¾ÇÂå°|¤]¦³¨D§U©ó¨àµ£Âå°|ªº®É­Ô¡AÄ´ ¦pMRI¡A¤j¾ÇÂå°|¥Ø«e¥¿¦b¸Ë¸m¤¤¡A¯f¤H»Ý°e¨Ó¨àµ£Âå°|¡A¥æ¬y¬OÂù­y¹Dªº¡C ¡@¡@¤p¨à¬ì¦³45¦ìM.D.ªº±M¾Âå®v¡A14¦W¬O¤ñ¸û¤@¯ë©Êªºªù¶E³¡¤Î«æ¶E³¡ªºÂå®v¡A¥L­Ì³£¬O¥þ ¾¡A½ü¬yºÊ·þ¦í°|Âå®v¤ÎÂå¾Ç¥Í¦b¦U³¡ªùªº¬¡°Ê¡C¦UºØªù¶E¤Î«æ¶E24¤p®É¤@©w¦³¥DªvÂå®v¦b³õ ­t³d¡C¥[Å@¯f©Ð¥Ñ­«¯f¦¸±M¬ì (critical care subspeciality) ¥DªvÂå®v¥DºÞ¡A¤£¦ý¬O¦í°| Âå®v24¤p®É¦b³õ¡A¥DªvÂå®v¤]»ÝÀH¥sÀH¨ì¡A·s¥Í¨à¬ì(neonatology)¥DªvÂå®v§ó¬O¥þ¤ÑÀ³­ÔÀ° ¦£¦í°|Âå®v¡C¨ä¥L¦U¦¸±M¬ì¦p¤ßŦ¡B¤º¤Àªc¡B­G¸z¡B¿ò¶Ç¾Ç¡B¦å²G¤ÎÀù½F¡B§K¬Ì¤Î¹L±Ó¡B¶Ç¬V ¯f¡BµÇŦ¦U¬ì¥~¡A¤]¦³±MºÞ¤p«Ä¦¨ªø(development)¥H¤Î«OÅ@(Protection)ªº¦U¤À¬ì¡C¨C¦¸±M ¬ì¤j¬ù¦³3¤H¥H¤W¡A¦³¨Ç¬ì¤]¦³«D±M¾ªº­Ý¥ô·þ®v¡C ¡@¡@¯f²z¬ì¦³4¦ì¥þ¾ªº¤p¨à¯f²zÂå®v¡A©ñ®g½u¬ì¤]¦³4¦ì(¥Ø«e1¦ìneuroradiology¥X¯Ê¡A¥Ñ§O ¤H­Ý¾)¬O±Mªù¤p¨à¤è­±¡C¥L­Ìªº¿ì¤½«Ç³£¦b¨àµ£Âå°|¤º¡A§ä¥L­Ì«D±`²³æ¤è«K¡C¤p¨à¯«¸g¬ì ¤Îºë¯«¬ì¤]¦U¦³´X¦ì±M¾Âå®v¦b¨àµ£Âå°|¡C¤ß²z¾Ç¤]¦³¦Û¤vªº¤@¬ì¡A¦³´X¦ì±M¾¤§ph. D.¤ÎºÓ ¤h¡A¥L­Ì»P¦¨ªø¦¸±M¬ì(developmental pediatrics) ²Õ¦¨¤@¬Û·í¤j³W¼Òªº¤¤¤ß¡A°£¤FÂå®v¡B ¤ß²z¾Ç®a¥~¡A¦³ªÀ·|¤u§@¤H­û¡B±Ð¨|¾Ç®aµ¥µ¥¥þ¾¤H­û¡C ¡@¡@¦³¨àµ£Âå°|³Ì¤jªº¦n³B¬O¨Ï¦U¥~¬ì±M¬ì¯à§ä¨ì¦³¤p¨à¸gÅ礧¦UºØ¥~¬ìÂå®vªø¾nÂå°|¡A±M¬° ¨àµ£³]·Q¡A¤£¥u¬O­Ý®tªº¤u§@¡C¤p¨à³Â¾K¦³5¦ì±M¾³Â¾KÂå®v¡A¤p¨à¤@¯ë¥~¬ì¦³3¦ì¥þ¾¤Î2¦ì ¦b¨àµ£Âå°|¤º¶}·~ªºÂå®v(¥L­Ì¨â¤H´X¥G©Ò¦³®É¶¡¦b¦¹Âå°|¡A¥L­Ìªºªù¶E¤]¯²¥ÎÂå°|ªº©Ð¶¡)¡C ¨ä¥L¤p¨àªº¯ÝµÄ¤ßŦ¥~¬ì¡B¯«¸g¥~¬ì¡B¾ã«¬¥~¬ì¡Bªc§¿¬ìµ¥µ¥¥~¬ìªº¦¸±M¬ì³£¦³1¤H¨ì¦n´X¤H±M ªù±q¨Æ¤p¨à¤è­±ªº¤u§@¡A¥L­Ì¸ò¨ä¥L¤H¤@¼Ë¡A¿ì¤½«Ç¤Îªù¶E®y¸¨©ó¨àµ£Âå°|¤º¡C¨ä¥L²´¬ì¡B¦Õ »ó³ï¬ì¡B°©¬ì³£¤@¼Ë¡C°ß¦³¤ú¬ì¤Î°ü²£¬ì¥u¦U½Ð1¦ì¶}·~Âå®v­Ý¥ô¡C ¡@¡@¤£¨ì200§É¤§Âå°|¡A¤£¥i¯à¼Ë¼Ë­Ñ³Æ¡A¯Ê¤Öªº³]³Æ¨ì¦¨¤Hªº¤j¾ÇÂå°|¥h­É¥Î©Î¥Ñ¥L­ÌÂå®v¸g ¤â¨Ï¥Î¡C¤p¨à¤ßŦ¬ìÂå®v¸g±`­n­É¥Î¤j¾ÇÂå°|¤ßŦ¾ÉºÞ«Ç³]³Æ¡A¥L­Ì´N±`±`©ê«è³]³Æ¤£¬°¤p¨à µÛ·Q¡A¥L­Ìªº«ØÄ³¥L¤£³Q±µ¨ü¡CÁö·Q¥Ñ¨àµ£Âå°|¦Û¤vÄw³]¦¹³]³Æ¡A¦ý¦Ü¤µ¤´¿ð¿ð¥¼¯à¶i¦æ¡A·Q ¨Ó¬O³]³Æ¤Ó¶Q¤F¡C¦UºØInterventional Radiology¤]¤£¥i¯à½Ð¨ì±Mªù¤p¨àªºÂå®v¡A¥u¦n­É­«¤j ¾ÇÂå°|¡B®Ö¤lÂå¾Ç³¡¡B©ñ®g½uªvÀø¥H¤Î¨ä¥L¦U¬ì¸û¤Ö¤H§Q¥Îªº³]¬I©Î±M®a¡C ¡@¡@¥Ñ©ó¦U¬ì±Mªù¤p¨àªºÂå®v³]³Æ³£®y¸¨©ó¨àµ£Âå°|¤º¡A¤j®a§ó¯à±M¤ßªA°È³yºÖ¯fµ£¡CÄ´¦p§Ú ­ÌÀù½F¬ì¡A¯fµ£­Y¦³Àù½F¡A¤£ºÞ¬O¥Ñ¤p¨à¬ì¡B¥ô¦ó¥~¬ì¡B±M¬ì©Î©ñ®g½u¬ìÂå®v°e¤J¡A¦³Ãö¤§Âå ®v°¨¤W´Nª¾¹D¡AÂå°|¤£¬Æ¤j¡AÁpµ¸¥L¤è«K¡A±`±`24¤p®É¤º´N¤@¤Á¶EÂ_§¹²¦¡A¯f²zÂå®v¤]³qª¾¨ì¡A ¦pªG©|¥½¶}¤M¡A¤j®a´N¦³¤@¦P·|¶Eªº¶É¦V¡C¨C1¬P´Á¦³Ãöªº¤p¨à¬ìÀù½FÂå®v¡A¦UºØ¥~¬ìÂå®v¡B©ñ ®g½u¬ìÂå®v¡B¯f²z¬ìÂå®v¡B©ñ®g½uªvÀøÂå®v¥H¤ÎÅ@¤h¡BÃÄ®v¡BªÀ·|¤u§@ªÌ¡B¤ß²z¾Ç®aµ¥µ¥¤S»E ·|¤@¦P°Q½×¦p¦óªvÀø¡C ¡@¡@¥H¤W³£¬O¦Û¤v¿Ë¨­ÅéÅç¦b¨àµ£Âå°|¤Î¤£¦b¨àµ£Âå°|¤§Àu¦H¡Aºâ¬O¸gÅç½Í¡A§Æ±æ¹ï¥xÆWÄw«Ø ¨àµ£Âå°|¦³©ÒÀ°¦£¡C

¦³®Ú¾ÚªºÂåÀø¤Î«ü¾É¤è°w(¤@) ²L½ÍEvidence-Based Clinical Practice and Guideline

¦¶¯u¤@ ¡@¡@³Ìªñ¦³¾÷·|Å¥¨ì¼Æ¦¸¦³Ãö¡u¦³®Ú¾ÚªºÂåÀø¡vªººtÁ¿¡A¤]¬Ý¨ìº¥º¥¦h°_¨Ó³oÃþ¤å³¹¦b ¬ü°êÂå¾ÇÂø»x¥Zµn¡C¬ü°ê¤º¬ì¾Ç·|(American College of Physician)ªºÂø»xAnnals of Internal Medicine¬Æ¦ÜÅP¦³¤@±MÄæ¡A¨C´Á°Q½×¦p¦ó¦¬¶°¬ì¾Ç®Ú¾Ú¨ÓÀ°¦£¤j®a°µ¶Eªvªº¨M ©w¡C³o¤@±MÄæ°Q½×¦p¦ó°µ¨t²Î¤Æªº¼f¾\(systematic review)©Î²Î­p¦X¨Ö¤ÀªR(meta- analysis)µ¥µ¥¨Ó±À¼s¦³®Ú¾ÚªºÂåÀø¡C ¡@¡@¶Eªv¯f¤H²o¯A¨ì¤£¤Ö½ÆÂøªº¦]¯À¡AÄ´¦p¬ì¾ÇªºÃÒ¾Ú¡A¯f¤H¤ÎÂå®vªº­Ó¤H¦]¯À¡AªÀ·| ©Î®a®xµ¥Àô¹Òªº¼vÅTµ¥µ¥¡C­Ó¤H¦]¯À¦p¤å¤Æ­I´º¡B±Ð¨|µ{«×¡B¸gÅç©Î­õ¾ÇÆ[ÂI³£¥i¼vÅT¡C ªk«ß¡BªÀ·|¸ê·½¡B¸gÀÙªº¤ä«ù¡BªÀ°Ï¼Ð·Ç§ó·|¥ª¥kÂå®v¦p¦ó¶Eªv¯f¤H¡C²{¦b¬ü°ê²±¦æªº HMO(Health Maintenance Organization)¨î«×©Î¥xÆW¥Ø«e¥þ¥Á°·«O¦h¤Ö³£¤w¤z¯A¨ìÂå®v ¶Eªvªº¤u§@¡C ¡@¡@¤W­z©Ò¦³ªº¦]¯À¤¤¡A¬ì¾Çªº®Ú¾ÚÀ³¬O³Ì­«­n¡A¦Ó¥B±N·|·U¨Ó·U­«­n¡C³o¤£¥u¬O¡u²z ©Ò·íµM¡v¤§¨Æ¡CªÀ·|¤Î¸gÀٸ귽ªºÀ£¤O¡A¤]·|¹G¨Ï¤j®a´Â¦¹¤è¦VÁÚ¶i¡C¦b¬ü°ê¤£¦ý¦p°© Åè²¾´Ó¡B¤ßŦ²¾´Óµ¥¶O¿úªºªvÀø¥ý­n±o¨ì«OÀI¤½¥qªº¼f®Ö¤~¯à°µ¡A¬Æ¦Ü¦p¹q¸£±½´y(CT scan)¡A®ÖºÏ¦@®¶±½´y(MRI)µ¥µ¥ÀËÅç¡A¬Æ¦Ü©ó°ò¥»ªº©ñ®g¾Ç©Î¤Æ¾Ç¦å²G¾ÇªºÀËÅç³£¥ý»Ý ­n¨Æ¥ýªº³\¥i¡A¤£µM«OÀI¤½¥q¤£¥I¿ú¡C«OÀI¤½¥q´N±`¥H¨S¦³¬ì¾Çªº®Ú¾Ú¬°²z¥Ñ¡A¤£§å­ã ¤@¨Ç©ù¶Qªº¶Eªv¡CÂå®v¤Î«OÀI¤½¥q³£¦³Âå¾Ç¤åÄm©Î¨ä¥LÃÒ¾Ú¨Ó¹ï¬Y¨Ç¶Eªv´£¨Ñ¬ì¾ÇªºÃÒ ¾Ú¡A¤£¯à¦A¥H¦Û¤vªº·N¨£¨Ó¨M©w¤F¡C ¡@¡@¬ì¾ÇªºÃÒ¾Ú¤]±`­n¤Wªk°|¡A¹³¤W¬q´£¤Îªº«OÀI¤½¥q®Ö­ãªº¶Eªv¡A­Y¤@¥¹³Q§_¨M¡A¦³ ¯f¤H¨ìªk°|±±§i«OÀI¤½¥q¹H¬ù¡CÂù¤è³£­n´£¥X¬ì¾Çªº®Ú¾Ú¨ÓÅG½×¡C­Y¦³ÂåÀøªÈ¯É¨º§ó¤£ ¥²Á¿¡A±±¤è¤Î³Q±±¤@¤è¤]³£®³¬ì¾Çªº®Ú¾Ú¬°¾Ì¾Ú¡C ¡@¡@¦]¬°ªÀ·|ªº¸ê·½¦³­­¥[¤WHMO«OÀI¨î«×·Q¾¨¶q¬Ù¿ú­­¨î¦UºØ¶Eªv¶O¥Î¡AÂå°|§ó¦]¬°·s ªº«OÀI¨î«×µ¹¥I´î¤Ö¦Ó¦³Àç¹B§xÃø¡A©Ò¥H¦U«OÀI¤½¥q¡B¦UÂå°|©Î¨ä¥L¾÷ºc¶}©l¥Xª©¦U¼Ë ¦U¦¡ªº«ü¾É¤è°w(guideline)¬°·í¬Y¨Ç¯e¯fªº¶Eªv¤è°w¡CÂå®v­Ì¡B¦U¯d¾Ç·|©Î±M¬ì¾Ç·|¤] ¶}©l¼g¨Ç¥t¥~¨¤«×¤£¦Pªº«ü¾É¤è°w©Î¥Î¤£¦P¦WºÙªº©Ò¿×Á{§É³~®|(clinical pathway)µ¥ µ¥¡C¥Ñ©ó¨C­Ó¼g«ü¾É­ì«h¯¸¦b¤£¦Pªº¥ß³õ¨Ó¬Ý¡A¦P¤@¯e¯f´N¦³³\¦h¤£¦Pª©¥»ªº«ü¾É¤è°w¡C ²{¦b¬ü°ê³oºØ«ü¾É¤è°w¥R¥¸¨Ï¤H¤£ª¾¦p¦ó¿ï¾Ü¤§·P¡C­Y­n¿ï¾Ü¦nªº«ü¾É¤è°w©Î­n§Üª§«O ÀI¤½¥q³W©wªº«ü¾É¤è°w¡A¤]¤@¼Ë»Ý­n¦³®Ú¾ÚªºÂåÀø¼Æ¾Ú¡C ¡@¡@¬ì¾Çªº®Ú¾Ú¤£¥u¬O¹êÅç«Çªº³\¦h¤é·s¤ë²§ªº·sµo²{¡A¤×¨ä¬O³Ìªñ¤À¤l¥Íª«¾Ç¤W¤@¤é ¤d¨½ªº¶i®i¡C³o¨Ç¹êÅç«Çªº¦¨´N§óÅý¶Eªv¯e¯f¬ì¾Ç¤Æ¡A¯à¨Ï¯f¦]§ó©ú®Ô¤Æ¡A¶EÂ_§ó·Ç½T¡C ¦ý¹ïÁ{§Éªº§à¿ï¡AÂåÀø°õ·~¤H­û¡AÁ{§Éªº¸ÕÅç(clinical trail)§ó¬O­«­n¡CªvÀø¤è¦¡¤] »Ý¬ì¾ÇªºªÖ©w¡C ¡@¡@Á{§É¸ÕÅ禳¤£¦PªººØÃþ¡A±q¤@­Ó¯f¨Òªº³ø§i¨ì¤W¤d¤W¸U¤HªºÂùª¼ÀH¾÷¨ú¼Ë¸ÕÅç(double blinded randomized trial)³£¬OÁ{§É¸ÕÅ窺®Ú¾Ú¡C¦p¦ó¿ï¾Ü¨ººØ¸ÕÅç¬O¥i¥H¨ú«Hªº¡A¦b Âå¾Ç¬É¦­¦³¦@ÃÑ¡C·U¬O¤Ö¼Æ¥Ø¯f¨Òªº¶Eªv³ø¾É·UÃø±Ä«H¨ä¶Eªvªºµ²ªG¡C¤£¹L¯f¨Ò³ø§i¥»¨­ ¨Ã¤£¤@©w¬O¨S¦³»ù­È¡A¤×¨ä¬O·sªº¶Eªvªk´¶³q¥Ñ¤Ö¼Æ(¬Æ¦Ü¤@­Ó)¯f¨Ò¶}©l¡C¯f¨Ò¼W¦h¦Ó®Ä ªG¤£¬Æ©ú½T®É¡A¥²¶·¦³¹ï·Ó¸s(control group)¸ÕÅç¨ÓÃÒ¹êªÖ©w¡C¸g±`¦³¨Ç¶}©l®É¦³¨Ç¶E ªvªk¦³ªì¨Bªº¦nµ²ªG¡A¦ý¤@¸g¹ï·Ó¸sªº¤ñ¸û¡A®ÄªG´N¨S¦³¤F¡C ¡@¡@Âå¾Ç¤W©ÒºÙªº¦w¼¢®ÄªG(Placebo effect)«Ü¥­±`¡A¤×¨ä¬O¯f¤H¥DÆ[¤Wªº·Pı©Î±¡ºü¥i ¥H¼vÅT¯f±¡©Î¯f¼xªº¯e¯f¡C¹³¯kµh¤£½×¬OÃö¸`ª¢¡B¨ü¶Ë©ÎÀù¯g¤Þ°_ªº¡A³£·|¦]·t¥Ü( suggestion)§@¥Î¦Ó¯à´î»´¯kµh¡C³Ìªñ¬Ý³ø³QÃÒ©ú¬O´ÛÄF¤Hªº¤Ó·¥ªù¡A¥L­Ì¥Î¡u«ô®v¡v¤Q´X ­ÓÄÁÀY¨å§¤¤¡AÅý¤H¶¼¡u¸t¤ô¡v³Q§@ªkªº«H®{´N·|¦³¯fµh¼È®É²¬Â¡ªº¦w¼¢®ÄªG¡C³o¡u«ô®v¡v ¤Î¡u¶¼¸t¤ô¡v´N¦³·t¥Üªº®ÄªG¡C ¡@¡@³Ì¥i¨ú«Hªº¬OÀH¾÷¨ú¼Ë¸ÕÅç¡A±N¯f¤H¤À¦¨¨â²Õ©Î§ó¦h²Õ¡A¨C²Õ¯f¤H²Õ¦¨ªº¯S¼xµL®t§O¡A ÀH¾÷¤À²Õ¡A¦U²Õ¥Î¤£¦Pªº§MÀøªk©Î¤£¦PÃĪ«¡C¯f¤H¤£¯à¤]¤£À³³Q·t¥Ü¨ººØªvÀø¦³®Ä¡C¦³ªº ÃĪ«¸ÕÅç³sªvÀø¤H­û¤Î¯f¤H³£¤£ª¾¬O¦óºØÃĪ«¡A³oºØÂùª¼ªº¸ÕÅç¡A¦bªvÀø¤H­û¯f¤H³£¤£ª¾ ±¡¤U¨Ó°µ¸ÕÅç¡A¨ÓÁ×§K¡u·t¥Ü¡v§@¥Î¡C³o¼ËªºÀH¾÷¨ú¼Ë¸ÕÅ纥º¥¦¨¬°¼Ú¬üÁ{§É¸ÕÅç³Ì¥D­n ªº¤u¨ã¡C ¡@¡@¥xÆW¸ò¼Ú¬ü¥H¤Î¥@¬É¨ä¥L¦U¦a¡A¥tÃþÂå¾Ç(alternative medicine)¤S¬y¦æ°_¨Ó¡C¦b¤@ ¥Zª«¤W¦³¤H¤£ª¾©~¤ß¦ó¦b§â³o¥tÃþÂå¾Ç½Ķ¦¨¡u§ï¨}¦¡Âå¾Ç¡v¡A³o¬O§¹¥þ»P¨Æ±G¤£²Å¦Xªº¡C ¤j³¡¤Àªº¥tÃþ¾¹¾Ç¤´¥¼¸g¹LÄY®æªºÁ{§É¸ÕÅç¡A¨Ï¥ÎªÌ¤´«Ü¦h¡C­ì¦]«Ü¦h¡A¤£¦b¦¹°Q½×¡A¦ý «OÀI¤½¥qªºµ¹¥I(©Î¦b¥xÆW¥þ¥Á«OÀI)¸ò¥DÃD¦³Ãö²¤¬°¤@½Í¡C ¡@¡@«e­±´£¨ì«OÀI¤½¥q¬°¤F´î¤Öµ¹¥I«Ü¬D­ç¦a­n¨D¦³¬ì¾Çªº®Ú¾Ú¡A¤£ªÖµ¹¥I©ù¶Qªº¶Eªv¡A ¦p°©Åè²¾´Ó¡B®ÖºÏ¦@®¶±½´yµ¥¡A¦ý¬O¦³¨Ç¤]Ä@µ¹¥I¤´¥¼¸gÄY®æÁ{§É¸ÕÅçÃҹꪺ¥tÃþÂå¾Ç¡C ³o¨Ç«OÀI¤½¥q¤´¬O¥H¡u¸gÀÙ±¾«Ó¡v¡A¥L­Ì¥u­n¯à´î¤Ö¤ä¥I´N¥i¥H§å­ã¡C¯f®a¤]Ä@§ä²©ö¡B ¤Öµh­W©Î¤Ö°Æ§@¥Îªº¥tÃþªvÀø¡A¦Ó¤£Ä@¥Î¥¿²Îªº¡B¦³¸gÁ{§ÉÀH¾÷¨ú¼ËÃҹꪺ¶Eªv¡C¥Î¨S¦³ ®Ú¾ÚªºªvÀø¡A®ÄªG¥¼ª¾¡A«á¨Ó¥i¯à¯f±¡¥[­«¡A¯f¤H¤S¦^ÀY¦A¥Î¥¿²ÎªºÂåÀø¡C¬Æ¦Ü©ó¤@¨Ç¥i ¯à¦ÛµM¥i²¬Â¡ªº¯fµh¡A¦³ªº²Î­p¥Î¨S¦³®Ú¾ÚªºªvÀøªk¡A¤]¤£¨£±o¸û¬Ù¿ú¡A¦]¬°¨C¦¸¶EÀø¶O ¦ü¥G¸û¤Ö¡A¦ý¶EÀø¦¸¼Æ«Ü¦h¡C¤´¥¼Àò±o¦³®Ú¾ÚªºÃÒ¹ê¡A¯f®a¤Î«OÀI¤½¥qªº¤ßºA¤Î§@¥Î¤´­È ±o¦Ò¼{¡C ¡@¡@¦b¥xÆW¤£¤Öªº¥tÃþÂåÀø¡A¤£¦ý¨S¦³Á{§É¸ÕÅ窺ÃÒ¹ê¡A§ó¬O©ù¶Q¡CÄ´¦pÅö?ªº¯f¼x¡A¤£ ¤Ö¯f®×¤¤¤F¥tÃþªvÀøªÌ¥i¥H¡uÂ_®Ú¡vªº«Å¶Ç«e©¹±µ¨üªvÀø¡C¾ÚºaÁ`¦¿«aµØÂå®vªº¤å³¹¡A¦³ ¥tÃþªvÀø¯f±w¨C­Ó¤ë¥­§¡ªáªº¶O¥Î¤ñ¥¿²Î¦èÃĪº¤j­¿ªºÃĶO¡A¦ý©Ò¦³¥u¦Y¥tÃþÂåÀø¯f±wªº ¦å²G¤¤§¡¦³¦èÃÄphenytoin©Îphenobarbitalªº§t¶q¡C³o¨Ç¥tÃþÂåÀøªºÃij£¥¼¸gÀˬd¼f®Ö¡A §ó¤£­n¸Ó¦³¤°»òÁ{§É¸ÕÅç¡C ¡@¡@­n§ä¬Y¤@¯e¯f©Î¨ä±¡ªp¨º¨Ç¶Eªv¦³§_®Ú¾Ú¡Hªñ¦~¨Ó¬ì¾Çª¾ÃÑÃz¬µ¦ü¿E¼W¡CÂå¾Çªº®Ú¾Ú ­n¾a¼Æ¾Ú(data)¡A³o¨Ç¼Æ¾Ú¤S¦p¦ó¨ú±o¡C¶Ç²ÎªºÂå¾ÇÂø»x¥~¡A¹q¤l´CÅé¤]º¥º¥¯¸¦í¦a¦ì¡A ¤×¨ä¬O¦]¸ê°T¬ì¾Çªºµo®i¡A¦UºØÂå¾Ç¸ê°TÀx¦s´M§ä¤ÀªR¡AÅܦ¨¦³®Ú¾ÚÂåÀøªº¨Ó·½¡C³o¨Ç±j ¦Ó¦³¤O¤S¦hªº¸ê°T¡A­Y¤£¥[¾ã²z¤ÀªR¡A¹ï¤@¯ëÂåÀø¤H­û¬O²@µL¥Î³Bªº¡C©Ò¥H¶}ÀY©Ò´£¤Îªº ¨t²Î¤Æªº¼f¾\¤Î²Î­p¦X¨Ö¤ÀªRÅܦ¨«D±`­«­n¡C¸Ô²Óªº¤¶²Ð³o¨Ç¼f¾\¤ÀªR±N¦b¤U¦¸¦A°Q½×¡C ¡@¡@¥H¤W©Ò¨¥·íµM¥u¬O¤@¨Ç½§²Lªº°Q½×¡A¥D­n¬O§Æ±æÂå¬É¤j®a¨Óª`­«±j½ÕÁ{§É¸ÕÅ窺­«­n¡A ¥H¤Î±Ä¨ú¦³®Ú¾Úªº¶Eªv¡C°ê¥~ªº¼Æ¾Ú¤]³\¤£¯à§¹¥þ¾A¦X¥xÆWªº¯f¤H¡C§Æ±æ±q¥xÆW¦Û¤vªºÆ[ ÂI¥h¶}©l°µ¼f¾\¤ÀªR¡A²Å¦X¦b¥xÆW°ê¤Hªº¼Æ¾Ú¡Aµ¹¤j®a¦³§ó©ú½Tªº«ü°w¡C

¦³®Ú¾ÚªºÂåÀø¤Î«ü¾É¤è°w(¤G) ­ìµo©Ê¯Ê¦å¤pªOµµ´³¶Eªv«ü¾É¤è°w¤§¨Ò

¦¶¯u¤@ ¡@¡@¤W¦¸²L½Í¦³®Ú¾ÚªºÂåÀø¤@¤å¤¤´£¤Î¦U±M¬ì¾Ç·|¬°¤FÂåÀøªº«ü¾É¤è°w(¥H¤U²ºÙ«ü°w)¦³ §ó¬ì¾Ç©Êªº®Ú¾Ú¡A¶}©l¬ãµo«ü°wªº¼g§@¡C³Ì¥D­n­ì¦]´N¬O­n¥[±j¼W¶iÂåÀøªº«~½è¡A´£°ªÂå Àøªº¤ô·Ç¡C±M¬ìÂå¾Ç·|¬O¤j®a¤½»{¡u²z©Ò·íµM¡v³Ì¦nªºÂåÀø«ü°wªº¬ãµo¾÷ºc¡A¤£¦ýÂå®v­Ì¡A ªÀ·|¦U¶¥¼h¥]¬A«OÀI¤½¥q³£¸û·|±µ¨ü¥Ñ±M¬ìÂå¾Ç·|©ÒÀÀ©wªº«ü°w¡C ¡@¡@¦]¦³¾÷·|°Ñ¥[¾Ç·|¥H¤Î¬ã°Q·|¤¤Å¥¨ì¬ü°ê¦å²G¾Ç·|­ìµo©Ê¯Ê¦å¤pªOµµ´³(idiopahic thrombocytopein purpura¥H¤U²ºÙITP)«ü°w¡A©e­û·|¥D®uDr. James George¤T¦¸ªººtÁ¿¡A ¨Ã¸ÔŪ¸Ó©e­û·|ªº¥Xª©¡A²`²`ı±o¸Ó©e­û·|ªº¤u§@¹ê¬O¤@­Ó«D±`¦n¼ËªO¡CÁöµM¸Ó·|¥Ø¼Ð¬O ¥»­n¼g§@¤@¦³®Ú¾Úªº¶Eªv«ü°w¡A¦ý¬O¥L­Ì«Ü§V¤O¦a¥h¦p¤W¦¸²L½Í¤@¤å©Ò´£¤Îªº¼f¾\¤ÀªR¡A µoı¨S¦³¨¬°÷ªº¼Æ¾Ú¨Ó¬°¦³®Ú¾Úªº¶Eªv«ü°w¦Ó§ï¥Î·N¨£½Õ¬d¤è¦¡¼g¥X«ü°w¡C¥L­Ì»s§@ªº¹L µ{©Ò¹J¨ìªº°ÝÃD¤Î·V­«ºA«×¤´­È±o°Ñ¦Ò¡A¦b¦¹¤£¹½¨ä·Ð³ø¾É¡C ¡@¡@³o¤@½gªº¸ê®Æ¥D­n¾a¬ü°ê¦å²G¾Ç·|(American Society of Hematology)ªº¾÷ÃöÂø»x Blood 1996¦~2¤ëªº¥þ¤å³ø¾É(1)¡A¬ü°ê¤º¬ì¾Ç·|ªºÂø»x1997¦~³Ìªñ¦³¸ûµuªº¤å¥I¥H¤Î²âÅ¥ ¤T¦¸ªººtÁ¿·|©Î¨ä¤¤°Q½×¦Ó¼g¦¨¡C ¡@¡@1993¦~¦³¨â¦ì¦å²G¾Ç·|ªº·|­û¡A¨ä¤¤¤@¦ì¬O¶}·~©e­û·|(committee on practice)ªº ¥D®u¡A¦V¦å²G¾Ç·|²z¨Æ·|½Ð¨D³]¥ß©e­û·|¨Ó¬ãµo¼g§@«ü°w¡C²z¨Æ·|³q¹L«á¨Ã¼·¤F¤Q¸U¬üª÷ ¬°¹wºâ¡C­º¥ý¨M©w¿ïITP¬°²Ä¤@­Ó¥Ø¼Ð¡A¿ïITP¦]¬°³o¬O¦å²G¾Ç¤¤¬Û·í¥­±`ªº¯e¯f¡A¦³¤£¤Ö ¶EÂ_¤ÎªvÀøªººÃÃø¡A¦³¤£¤Öª§ÅG¬Y¨Ç¶EÂ_©Î¬Y¨ÇªvÀø¬O§_¦³®Ä¡B¬O§_¦w¥þ¡B¬O§_»Ý­n¡C·í ®Éªº¦å²G¾Ç·|´N¿ïOklahoma¤j¾Ç¦å²G¾Ç¬ì¥D¥ôJames George¬°¸ÓITP«ü°w©e­û·|¥D®u¡C ¡@¡@1994¦~6¤ë¥D®u¿ï¾ÜÁܽФF¨ä¥L14¤H¬°©e­û·|¦¨­û¡A¨ä¤¤¤@¦ì¬OÁ{§É¬y¦æ¯f¾Ç®a (clinical epidemiologist)¤@¦ì¬O±MªøÂå¾Ç«ü°w¬ãµo¼g§@ªº¤èªk½×®a(methodologist)¡C ¨ä¥L12¦ì(¥]¬A¥D®u¦@13¦ì)¬O¦å²G¾Ç®a¡C9¦ì¬O¤j¾ÇÂå°|ªº¾Ç°|¦¡¦å²G¾Ç®a(6¦ì¤º¬ì¡A3¦ì ¤p¨à¬ì)¡A4¦ì¬O¶}·~ªº¦å²G¾Ç®a¡C ¡@¡@©e­û·|²Ä¤@­n°È¬O·V¿ï¥Ø¼Ð¡A¥ý­­©w©Ò¿×¤§ITP½T©w¦b­ìµo©Ê(Idiopathic)¤W¡C¦]¦¹ ¯f¨Ã¨S¦³¤@¯S§O¥i«H¿à¡B¥i¥H¶EÂ_ªº¤èªk¡A¥²»Ý¾a±Æ°£¨ä¥L¤]·|¤Þ°_¦å¤pªO´î§Cªº¯e¯f¡C ­º¥ý¨M©w¤£°Q½×¡A¦]¦³¨ä¥L¯e¯f¡A¦Ó¤Þµoªº§K¬Ì©Ê¯Ê¦å¤pªOµµ´³¯g¡C¥ýÂê©w¥Ø¼Ð¡C ¡@¡@µM«á¥h·j´M¤åÄm¡C¥ý±q¦UºØ¤£¦P¸ê°T³nÅ餤§ä¥X¦³Ãö¤§¤åÄm¡AµM«á¥Ñ¦U©e­û¸ÔŪ¡A ¦A¥[¤W¨C¤H©Òª¾¦Ó¥¼³Q¦¬¶°¨ìªº¤åÄm¡C¤åÄm¼Æ¥Ø¹ê¦b¤Ó¦h¤£¯à¤@¤@¸ÔŪ¡C­º¥ý²M°£¤@¨Ç ¯f¨Ò³ø§i¡A¤Ö©ó¤­­Ó¯f¨Òªº¨t¦C³ø¾É¡A©Î¦UºØ¨S¦³­ì¥»¼Æ¾Úªº¤åÄm³ø§i¡C¨C¤@¤åÄm¥Ñ©e ­û·|¤¤¨â¤H¦U¦Û¿W¥ßµû¦ô¨C­Ó¤åÄmªº¬ì¾Ç»ù­È¤Î¨äµ²ªG¡C ¡@¡@¥L­Ì¤G¤H§â³o¨Ç¤åÄmµû¦ô¤Àµ¥¡A§â¶Eªv®ÄªG¨Ì¼Æ¾Ú¤§¦nÃa¤À¦¨¤­µ¥¯Å¡C³Ì±j¦³¤Oªº¡A ·íµM¬O¤Ö°²©Ê¥¿­±­t­±(false positive or negative)¿ù»~ªºÀH¾÷¨ú¼Ë¸ÕÅç(randomized trial)¡A¨ä¦¸¬O¸û¦h°²©Ê¿ù»~ªºÀH¾÷¨ú¼Ë¸ÕÅç¡C²Ä¤Tµ¥¯Å¬O¨S¦³ÀH¾÷¨ú¼Ë¡A¦ý¦³¹ï·Ó¸s (control)ªº¸ÕÅç¡A²Ä¥|¬O¥Î¥H«e¾ú¥v©Ê¼Æ¾Ú¬°¹ï·Ó¸sªº¡A²Ä¤­¯Å¤]´N¬O³Ì®z¦ÓµL¤Oªº¬O ¯f¨Ò¨t¦C¨S¦³¹ï·Ó¸sªº¡C ¡@¡@¥L­Ìµo²{µ´¤j¦h¼ÆªºÁ{§ÉªvÀø³ø§i¡A¤j³£¬O²Ä¤­¯Å³Ì®z¦ÓµL¤O¨S¦³¹ï·Ó¸sªº¸ÕÅç¡A ©Ò¥H®Ú¥»µLªk¤ÀªR¬ãµo¼g§@¤@¦³®Ú¾Úªº«ü°w¡C·íµM¥u¦n°h¦Ó¨D¨ä¦¸¡A¥H¡u·N¨£½Õ¬d¡v¬° ¥D­nªº¤èªk¡C ¡@¡@¯S§O¬°¤FÁ×§K¤@¨Ç·RÁ¿¸Ü¤S¦³±j¯P·N¨£©e­û·|¥i¯à¤ä°t¥ª¥k¨ä¥L©e­û­Ìªº·N¨£¡A©Ò ¥H¤£¥ý°Q½×¨C¤H¬Ýªk¦p¦ó¡A¨C¤H³£±o¨ì³o¨Ç¤åÄmªº½Æ¥»¤Îµû¦ôµ²ªG¡A¤j®a¿W¥ß¤À§O¦³¥R ¤À®É¶¡¦b¦Û¤v¿ì¤½«Ç¦^µª°Ý¨÷¡C²Ä¤@³¡¤À¦b1994¦~¦³41­¶1300¦UºØ¤£¦PªºÁ{§É±¡ªpªº°Ý ÃD¡A¶l±Hµ¹©e­û­Ì¦^µª¡A1995¦~ªì¥t¥[¤W25­¶¦³600­Ó°ÝÃD°Ý¨÷¡C ¡@¡@³o¨Ç°Ý¨÷ªº°ÝÃD¤£¦ý°Ý¹ïªvÀøªº·N¨£¡A¤]°Ý¶EÂ_ªº·N¨£¡C¦¨¤H¡B¤p«Ä¡B¥¥°ü¤Î·s¥Í ¨à¤À§O³B²z¤£¦PÁ{§É±¡ªp¡C³o·N¨£½Õ¬d®É©e­û·|¨M©w¤j®a¥Î¤½¦Pªº©w¸q¨Óªí¹F·N¨£¡A¦³ ¬Û¦Pªº¼Ð·Ç¡A²Î­p¼Æ¾Ú¤~·|¦³·N¸q¡CÄ´¦p¥²»Ýªº¬O«ü¬YºØ¶EÂ_ªk©ÎªvÀø¬O¥²»Ý°µªº¡A¦ý ­Y¬O§´·í§_«h«ü¶Eªv¥i¯à¬O¤]¥i¯à¤£¬O¥²»Ýªº¡A¦ý¨Ã¤£¿ù¡C¤Ï¹L¨ÓµL»Ýªº«h¬O¬YºØ¶Eªv ¤£»Ý­nªº¡A¦ý¤£¤@©w¬O¤£§´·í¡C³o¤£§´·í¬O¤£·í¤]¬O¤£À³¸Ó¥h°µªº¡C ¡@¡@¬°¤FÅý¦UºØ·N¨£ªº²§¦P¥i¥H¿Å¶q¡A¨C¤H·N¨£¬O§_¤@­P¡A©e­û·|±Ä¥Î¤@ºØRandªº°O¤À ªí¨ÓÅý©e­û­Ìªí¹F·N¨£¡A¨C­Ó©e­û¹ï¨C¤@±¡ªp¥i¥H¥Î1-9¥´¤À¼Æ¡A9¬O³Ì¦P·N¡A1³Ì¤£¦P·N¡A ¨ä¶¡¦³¤£¦PªÅ¶¡¡C¥­§¡ªº¤À¼Æ¤j©ó7«h·í°µ¥­§¡¤W¤jÅé¦P·N¡A¥­§¡§C©ó3¤À«hªí¤£¦P·N¡C ¡@¡@©e­û¶¡ªº¤@­P©Ê§_«h¥ÎA¡BB¡BC¡BD¡BE¨Óªí¥Ü¡A³oA¨ìEªºµ¥¯Å¬O©w¸q¦p¤U¡GA¬O§¹¥þ ©Î®t¤£¦h§¹¥þ¤@­P¡A«ü©e­û·|·|­û¶¡®t²§§C©ó¥­§¡®t²§2­Ó¼Ð·Ç°¾®t(SD¡Astandard deviation)¥H¤W¡AB¬O«D±`¤@­P¡A«ü©e­û·|¶¡ªº®t²§¬O§C©ó¥­§¡®t²§1-2­ÓSD¶¡¡AC¬O¬Û ·í¤@­P¡A«ü©e­û·|¶¡ªº®t²§§C©ó¥­§¡®t²§¤@­ÓSD¥H¤º¡CD¬O¬Û·í¤£¤@­P¡A«ü©e­û·|¶¡ªº ®t²§°ª©ó¥­§¡®t²§¤@­ÓSD¥H¤º¡CE¬O«D±`¤£¤@­P¡A«ü©e­û·|¶¡ªº®t²§°ª©ó¥­§¡®t²§¤@­Ó SD¥H¤W¡C ¡@¡@©Ò¥H¬Y¨Ç¶µ¥Ø¥H1.5¡AA«hªí¥Ü©e­û«D±`±j¯P´X¥G¤@­P¦a»{¬°¬YºØ¶Eªv¬O¤£»Ý­n©Î¤£ §´·í¡C7.5¡AD«h¬Û¤Ï¡A¹ï¥t¤@ºØ¶Eªv¶µ¥Ø©e­û­Ì¬Û·í¤£¤@­P¦a»{¬°»Ý­n©Î§´·í¡A¦ý©e­û ¶¡¦³¬Û·í¤£¤@­P¡B¤£¤@¼Ëªº·N¨£¡C©e­û·|¨M©w¥H¥­§¡§C©ó3ºÙ¬°¤£¦P·N¡A°ª©ó7¬°¦P·N¬Y ¤@¶Eªvªº»Ý­n©Ê©Î§´·í©Ê¡C ¡@¡@³oºØ¤èªk¥Î¨Óµû¦ô¹ï»Ý­n©Ê©Î§´·í©Ê¥i¯à¦³¤£¦Pµ¥¯Åªº¦P·N©Ê©Î¤@­P©Ê¡CÄ´¦p¹ï¦¨ ¤H¦³ITP®É¡A°©Åè¬ï¨ë¬O§_»Ý­n©Î§´·í§_¡C°Ý§´·í§_¥­§¡¥u¦³5.3¤À¡A¥B«D±`¤£¤W­P(§Y E¯Å)¡A¦ý¶¡»Ý­n§_«h§ó´î¬°3.6¤À¤Î¬Û·í¤£¤@­P(D¯Å)¡C¥i¨£»Ý­n©Ê§C©ó§´·í©Ê¡A¤]´N¬O »¡¦³¨Ç¤H»{¬°¤£»Ý­n¦ý¨Ã¨S¦³¤°»ò¤£§´·í¡C ¡@¡@¤p«ÄITP¦b¤£¦Pµ{«×ªº¦å¤pªO¼Æ¥Ø¡A¦Ó¥u¦³»´·L¥X¦å¯gª¬®É¡A¤£ªvÀø¬O§_§´·í§_¡C¤] ¥i¬Ý¥X©e­û­Ì¶¡¤@­P©ÊÀH¦å¤pªO¼Æ¥Ø¦³¤£¦P¡C¦p¦å¤pªO§C©ó10,000®É¡A©e­û­Ì¬Û·í¤£¤@ ­P(D¯Å)¦a¤£¦P·N(2.5¤À)¤£ªvÀø¬O§´·íªº¡AÀHµÛ¦å¤pªO¼Æ¤É°ª«h·U¨Ó·U¦P·N¡B·U¤@­P¦a »{¬°¤£ªvÀø¬O§´·íªº¡CÄ´¦p¦å¤pªO30,000¨ì50,000®É¡A´N¬Û·í¤@­P¦a¦P·N(8.3¤ÀC¯Å¤@­P ©Ê)¤£¥²ªvÀø¡A·í¦å¤pªO¼W¨ì¤j©ó50,000®É¡A©Ò¦³©e­û³£¤@­P¦a¦P·N¤£¥²ªvÀø(9.0¤ÀA¯Å ¤@­P©Ê)¡C¥i¨£³\¦hªº¶Eªv¥u¬O·N¨£Æ[ÂI«D¦³¬ì¾ÇªºÃÒ¾Ú¡C ¡@¡@©Ò¥H©e­û·|¥u¦n¥Î³o¨ÇÁÙ¬Û·í¤£¤@­Pªº·N¨£¨Ó¬°³oITPªº«ü°w¡C¥u¬O¡u·N¨£©Êªº«ü°w¡v ¤£¬O¦³®Ú¾Ú©Êªº«ü°w¡C·í¥L­Ì§â«ü°w¼g¦n«á¡A¥ýÅý¨ä¥L¤£¬O©e­û­Ìªº¨ä¥L8¦ì¦å²G¾Ç®a¹L ¥Ø§åµû¡A¥H«á¦A¥Xª©³o«ü¾É¤è°w¡C³oITPªº«ü°w¦³³\¦h±ÀÂˬO«Ü¦nªº°Ñ¦Ò¸ê®Æ¡A·í¥t¤å¤¶ ²Ð¡C³oùØ¥u°Q½×«ü°wªº¬ãµo¤Î·P·Q¡C ¡@¡@³o¬ãµo«ü°wªº¹Lµ{¡A§Ú¬Û«H«Ü¦h¤H³£¦³©Òì¡C¦b¦å²G¾Ç¬É³o¥u¬O°_ÂI¡A³Ì¤jªº±Ð°V¬O ¤j®a§ó²M·¡¦aª¾¹D¡A¦³®Ú¾ÚÂåÀøªº«ü°wªº½T¬Û·í§xÃø¼g§@¡C¤j®a¤]¦]¦Ó§ó¤F¸Ñ¥H«á°µÁ{§É ¸ÕÅ礣¯à¥u¦³¨t¦C¡AÀ³¦³¹ï·Ó¸s¥B­nÀH¾÷¨ú¼Ë(randomized)¤~³Ì¦³·N¸q¡C ¡@¡@¬Ý³o¬ãµo³o«ü°w¤¤¡A¦³¤@ÂI§ó­n´£¥Xªº¬O¡A¨Ï¤j®a¤F¸Ñ¨ì¤°»ò¬O¯uªº¦³®Ú¾Ú¬O¯uª¾¡A ¤°»ò¬O¤£ª¾¹DªºªF¦è¡C³oºØ©Ó»{¤£ª¾¹D¤]¬O¤@ºØ»{ª¾¡A³o¸ò¡uª¾¤§¬°ª¾¡A¤£ª¾¬°¤£ª¾¬Oª¾ ¤]¡vªººë¯«­Ë¬O¤@­P¡C ¡@¡@¥t´XÂI§Ú©Òı¹î¦Ó­n«ü¥Xªº¬O¡A¦b¬ü°ê¶}·~Âå®v«D±`³Q´L­«¡A©e­û­Ì¥H¤Î¥H«á§å¨Ñ§å µûªº¦å²G¾ÇÂå®v¡A¤£¤Ö¬O¶}·~Á{§ÉÂå®v¡A¤£¥þ¬O¾Ç°|¬£ªº¾Ç³N¨ú¦Vªº¤j¾ÇÂå°|Âå®v¦Ó¤w¡C ³o«ü°w¨Ã¨S¦³°µ¶Eªvªº¦¨¥»µû¦ô¡A¦b³ø§i¤¤´¿´£¤Î³o±N¬O¥H«áªº¥Ø¼Ð¤§¤@¡C ¡@¡@«ü°w¨Ã¤£¬O¡u¼Ð·Çµª®×¡v¡A§@ªÌ­Ì¤]¦b¤å¤¤´£¥X¡A¥H«á¦³·sªº¼Æ¾Ú¤]»ÝÄ~Äò§ó§ï¡C¦ý µL½×¦p¦ó³o«ü°wªºµoªí¹ïITPªº¶Eªv¦³³\¦h²`ªº¼vÅT¡A¤]·|§ïÅܩΥ[²`¤@¨Ç¦å²G¾Ç®a¶Eªv ITPªºÆ[©À¡C§Æ±æ¨ä¥L±M¬ì¤]¦h¦h¥hµo®i¬ã¨s§ó¦hªº«ü°wµ¹¤j®a·í¶Eªvªº°Ñ¦Ò¡A¤]¼W¶iÂåÀø ªº«~½è¡A´£°ªÂåÀøªº¤ô·Ç¡C °Ñ¦Ò¤åÄm 1.George JN, Woolf SH, Raskob GE, et al: Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology Blood, 1996; 88: 3-40. 2.The American society of hematology ITP practice guideline panel clinical guideline, diagnosis and treatment of idiopathic thrombocytopenic purpura: Recommendations of American Society of Hematology.Ann Int Med:1997; 126:319-326. --------------------------------------------------------------------- ½Ð ÃÙ §U¡A ½Ð ¶} CHECK µ¹NATPA¡ANON-PROFIT ORGANIZATION ¤j ¦W ¡R º~¦r¡R_________________________________ENGLISH:__________________ ¦í §} ¡R _________________________________________________________________ ½Ð ±H ¨Ó NATPA, P. O. BOX 22, CHESTERFIELD, MO 63006 ©Î E-mail : alchu@i1.net ___________________________________________________________________ Any comment and question,please send to Albert Chu Link to: «È ¥x »y ±M ¥Z ¦U ´Á Link to:TAIWANESE HAKKA ¥x ÆW «È ®a (ENGLISH) Link to:HAKKA TAIWANESE RESOURCES «È ¥x »y ¸ê ®Æ ®w Link to:HAKKA TAIWANESE HAKKA CULURE ¥x ÆW «È ®a ¤å ¤Æ ±M ¥Z Link to:TAIWANESE MEDICAL HISTORY ¥x ÆW Âå ¾Ç ¥v ±M ¥Z Link to: TAIWAN RELATED ARTICLES ¥x ÆW ±M ¥Z